These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15755685)

  • 1. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism.
    Fernandez-Espejo E; Caraballo I; de Fonseca FR; El Banoua F; Ferrer B; Flores JA; Galan-Rodriguez B
    Neurobiol Dis; 2005 Apr; 18(3):591-601. PubMed ID: 15755685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function.
    Fernandez-Espejo E; Caraballo I; Rodriguez de Fonseca F; Ferrer B; El Banoua F; Flores JA; Galan-Rodriguez B
    Neuropsychopharmacology; 2004 Jun; 29(6):1134-42. PubMed ID: 15010694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model.
    El-Banoua F; Caraballo I; Flores JA; Galan-Rodriguez B; Fernandez-Espejo E
    Neurobiol Dis; 2004 Jul; 16(2):377-85. PubMed ID: 15193294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
    FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.
    Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R
    Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
    McPherson RJ; Marshall JF
    Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
    Schoffelmeer AN; Hogenboom F; Wardeh G; De Vries TJ
    Neuropharmacology; 2006 Sep; 51(4):773-81. PubMed ID: 16806307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
    Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors.
    Andersson DR; Björnsson E; Bergquist F; Nissbrandt H
    Exp Neurol; 2010 Jan; 221(1):251-9. PubMed ID: 19944096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.
    García-Arencibia M; Ferraro L; Tanganelli S; Fernández-Ruiz J
    Neurosci Lett; 2008 Jun; 438(1):10-3. PubMed ID: 18457923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
    Mela F; Marti M; Bido S; Cenci MA; Morari M
    Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo models of multiple system atrophy.
    Fernagut PO; Ghorayeb I; Diguet E; Tison F
    Mov Disord; 2005 Aug; 20 Suppl 12():S57-63. PubMed ID: 16092092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
    Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
    Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C; Kirik D; Björklund A
    Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
    Löschmann PA; De Groote C; Smith L; Wüllner U; Fischer G; Kemp JA; Jenner P; Klockgether T
    Exp Neurol; 2004 May; 187(1):86-93. PubMed ID: 15081591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy).
    Scherfler C; Sather T; Diguet E; Stefanova N; Puschban Z; Tison F; Poewe W; Wenning GK
    J Neural Transm (Vienna); 2005 Aug; 112(8):1025-33. PubMed ID: 15583958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.